2 recruiting. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
Follow EIK1001: new trials by email Literature Review of EIK1001 trials Research Report on EIK1001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. EIK1001, Pembrolizumab (KEYTRUDA®), Placebo - Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 750 | 2026-06-15 | 2026-11-16 |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. EIK1001, Pembrolizumab (KEYTRUDA® ) - Advanced Melanoma | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 740 | 2025-05-22 | 2026-10-06 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1)
Australia (2) · Austria (2) · Belgium (2) · Germany (2) · Italy (2) · Poland (2) · South Africa (2) · South Korea (2) · Spain (2) · United States (2) · Argentina (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1)
Etah Kurland (1) · Muaz Sadeia (1) · Nishitha Reddy (1)
2025 (1)